Zynerba Pharmaceuticals (ZYNE)

[cjstocksup]

That was a follow up to this analyst upgrade to Overweight and $17.00 per share ZYNE PPS target.
ZYNE upgraded to $17.00. Look for more of these.
UPDATE: Cantor Fitzgerald Upgrades Zynerba Pharmaceuticals (ZYNE) to Overweight
October 2, 2017 5:55 AM

(Updated - October 2, 2017 6:54 AM EDT)


(updated to add analyst comment)

Cantor Fitzgerald upgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Neutral to Overweight with a price target of $17.00 (from $4.00).

Analyst Elemer Piros cites the phase 2a data in Fragile X syndrome noting encouragement from the potential for ZYN002 in treating the disease. The analyst sees upside catalysts from additional regulatory clarity on late-stage development which is slated for 2018.

For an analyst ratings summary and ratings history on Zynerba Pharmaceuticals click here. For more ratings news on Zynerba Pharmaceuticals click here.

Shares of Zynerba Pharmaceuticals closed at $8.36 Friday.
https://www.streetinsider.com/dr/news.php?id=13346899&gfv=1